BridgeBio Pharma, Inc.
BBIO
$38.34
$0.320.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -167.42M | -265.05M | -162.04M | -73.46M | -35.22M |
| Total Depreciation and Amortization | 1.28M | 1.37M | 1.54M | 1.57M | 1.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.07M | 55.41M | -17.92M | -99.85M | 39.28M |
| Change in Net Operating Assets | -116.17M | 12.95M | -2.14M | 246.44M | -225.20M |
| Cash from Operations | -199.24M | -195.33M | -180.57M | 74.70M | -219.54M |
| Capital Expenditure | -- | -47.00K | -137.00K | -54.00K | -695.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | -42.00K | -98.00K | -- |
| Other Investing Activities | -1.60M | -3.19M | 38.41M | 3.19M | 23.45M |
| Cash from Investing | -1.60M | -3.24M | 38.23M | 3.04M | 22.75M |
| Total Debt Issued | 575.00M | 500.00M | 0.00 | 0.00 | 450.00M |
| Total Debt Repaid | -459.00M | 0.00 | 0.00 | 0.00 | -473.42M |
| Issuance of Common Stock | 5.76M | 2.85M | 2.15M | -- | 318.16M |
| Repurchase of Common Stock | -50.05M | -1.40M | -1.44M | -2.00M | -2.94M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.38M | -27.51M | 0.00 | -3.73M | -12.25M |
| Cash from Financing | 60.33M | 473.93M | 707.00K | -5.73M | 279.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.50M | 275.37M | -141.63M | 72.01M | 82.76M |